Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund (BIVF) is the corporate venture arm of pharma group Boehringer Ingelheim, launched in 2010 and headquartered in Ingelheim am Rhein, Germany. It runs a 350 million euro evergreen fund investing globally (EU, US, China) as a dedicated Seed/Series A biotech investor, backing first-in-class disease-modifying therapeutics across immuno-oncology, regenerative medicine, auto-immunity, anti-infectives (AMR) and digital health. It typically takes a minority stake with a board seat, has invested in over 70 companies, and has produced multiple exits including six acquisitions by its own parent.
Boehringer Ingelheim Venture Fund is an Ingelheim am Rhein venture capital firm with €350M AUM, 31 active companies and 14 exits.
- ·4 exits in the last 5 years · consistent DPI cadence.
- ·Average hold across 13 realized deals: 5 years.
- ·Top sector focus: Biotech (89% of portfolio).
Sector breakdown
45 companiesGeography breakdown
12 geographiesKey facts
Recent exits
Boehringer Ingelheim Venture Fund took AgomAb Therapeutics public in 2026 after 7 years.
Boehringer Ingelheim Venture Fund sold ImCheck Therapeutics to Ipsen in 2025 after 8 years.
Boehringer Ingelheim Venture Fund sold T3 Pharmaceuticals to Boehringer Ingelheim in 2023 after 4 years.
Boehringer Ingelheim Venture Fund sold Abexxa Biologics to Boehringer Ingelheim in 2021 after 5 years.
Coverage notes
1 fund tracked, 45 portfolio companies (31 active · 14 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Boehringer Ingelheim Venture Fund has raised, with its portfolio companies. Hand-checked from public filings.
Boehringer Ingelheim Venture FundActiveEvergreen2010€350M31 assets14 exitsEvergreen2010 · 16yr€350M3114
Unrealized
31 held| Company | Entry |
|---|---|
| Abalos Therapeutics Biotech · Germany | 2019 |
| Acousia Therapeutics Biotech · Germany | 2012 |
| Aignostics HealthTech · Germany | 2020 |
| ArrePath Biotech · US | 2021 |
| Asgard Therapeutics Biotech · Sweden | 2021 |
| Aurobac Therapeutics Biotech · France | 2023 |
| Bodyport HealthTech · US | 2020 |
| Brainomix HealthTech · UK | 2018 |
| C-mo Medical Solutions HealthTech · Portugal | 2022 |
| Centauri Therapeutics Biotech · UK | 2022 |
| DiogenX Biotech · France | 2020 |
| EvlaBio Biotech · Germany | 2025 |
| Glox Therapeutics Biotech · UK | 2023 |
| HepaRegenix Biotech · Germany | 2016 |
| Libra Therapeutics Biotech · US | 2020 |
| Nuevocor Biotech · Singapore | 2021 |
| Obulytix Biotech · Belgium | 2023 |
| ProTgen Biotech · US | 2024 |
| QUANTRO Therapeutics Biotech · Austria | 2020 |
| Refoxy Pharmaceuticals Biotech · Germany | 2024 |
| Rewind Therapeutics Biotech · Belgium | 2017 |
| Rgenta Biotech · US | 2019 |
| RiboX Therapeutics Biotech · China | 2021 |
| RinRi Therapeutics Biotech · UK | 2019 |
| smartbax Biotech · Germany | 2021 |
| Strm.bio Biotech · US | 2021 |
| SwitchKine Biotech · Switzerland | 2024 |
| Synthetica Pioneering Biotech · China | 2024 |
| Tacalyx Biotech · Germany | 2019 |
| TECregen Biotech · Switzerland | 2023 |
| Topas Therapeutics Biotech · Germany | 2017 |
Realized
14 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Abexxa Biologics Biotech · US | 2016 | 2021 | Trade Sale | Boehringer Ingelheim | – |
| AgomAb Therapeutics Biotech · Belgium | 2019 | 2026 | IPO | – | – |
| Amal Therapeutics Biotech · Switzerland | 2016 | 2019 | Trade Sale | Boehringer Ingelheim | – |
| ArmaGen Technologies Biotech · US | 2014 | 2020 | Trade Sale | JCR Pharmaceuticals | – |
| Hookipa Pharma Biotech · Austria | 2013 | 2019 | IPO | Sofinnova Partners | – |
| ICD Therapeutics Biotech · Germany | – | 2019 | Trade Sale | Boehringer Ingelheim | – |
| ImCheck Therapeutics Biotech · France | 2017 | 2025 | Trade Sale | Ipsen | – |
| NBE Therapeutics Biotech · Switzerland | 2013 | 2020 | Trade Sale | Boehringer Ingelheim | – |
| Okairos Biotech · Switzerland | 2011 | 2013 | Trade Sale | GlaxoSmithKline | – |
| Rigontec Biotech · Germany | 2014 | 2017 | Trade Sale | Merck | – |
| STAT-Dx HealthTech · Spain | 2013 | 2018 | Trade Sale | Qiagen | – |
| T3 Pharmaceuticals Biotech · Switzerland | 2019 | 2023 | Trade Sale | Boehringer Ingelheim | – |
| Tilos Therapeutics Biotech · US | 2016 | 2019 | Trade Sale | Merck | – |
| ViraTherapeutics Biotech · Austria | 2013 | 2018 | Trade Sale | Boehringer Ingelheim | – |
Frequently asked questions
- What investment strategy does Boehringer Ingelheim Venture Fund focus on?
- Boehringer Ingelheim Venture Fund focuses on VC strategies in the private equity space.
- How many portfolio companies does Boehringer Ingelheim Venture Fund have?
- Boehringer Ingelheim Venture Fund has 31 active portfolio companies and 14 completed exits and 1 fund tracked on GP Intel.
- Where is Boehringer Ingelheim Venture Fund headquartered?
- Boehringer Ingelheim Venture Fund is headquartered in Ingelheim am Rhein, Germany.
- What is Boehringer Ingelheim Venture Fund's assets under management?
- Boehringer Ingelheim Venture Fund manages approximately €350M in assets under management.
- When was Boehringer Ingelheim Venture Fund founded?
- Boehringer Ingelheim Venture Fund was founded in 2010.
- What sectors does Boehringer Ingelheim Venture Fund invest in?
- Boehringer Ingelheim Venture Fund invests across Healthcare.
- What are Boehringer Ingelheim Venture Fund's recent exits?
- Recent realized exits by Boehringer Ingelheim Venture Fund include: ImCheck Therapeutics (2025) to Ipsen; T3 Pharmaceuticals (2023) to Boehringer Ingelheim; Abexxa Biologics (2021) to Boehringer Ingelheim; ArmaGen Technologies (2020) to JCR Pharmaceuticals; NBE Therapeutics (2020) to Boehringer Ingelheim; Amal Therapeutics (2019) to Boehringer Ingelheim; Hookipa Pharma (2019) to Sofinnova Partners; ICD Therapeutics (2019) to Boehringer Ingelheim.
Similar firms
Other private equity firms tracked on GP Intel.
Germany·€350M
Germany·€315M
Germany·€400M
Germany·€300M
Germany·€300M
Germany·€400M
Germany·€400M
Germany·€300M
Germany·€400M
Germany·€300M
Germany·€298M
Germany·€283M